The trial is taking place at:
P

Pinnacle Research Group | Anniston, AL

Veeva-enabled site

ConsideRAte Study - Splenic Stimulation for RA

G

Galvani Bioelectronics

Status

Enrolling

Conditions

Rheumatoid Arthritis

Treatments

Drug: Baricitinib
Device: Active Stimulation
Device: Sham Stimulation
Drug: Background Treatment

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT05003310
GAL1040

Details and patient eligibility

About

This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and accessories. The study will consist of 4 study periods, including a Randomized Control Trial period (Period 1), an Open Label period (Period 2), a Treat-to-target period (Period 3), and a Long-term Follow-up period (Period 4). Participants eligible for implant will have active rheumatoid arthritis (RA) and have an inadequate response or intolerance to at least two biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) or JAK inhibitors (JAKis). A sufficient number of participants will be enrolled so that approximately 28 participants will undergo device implantation.

Full description

Participants with active rheumatoid arthritis (RA) who receive the implantable system will be randomly assigned to receive either active stimulation or sham-stimulation for 12 weeks (Period 1). Following Period 1, all participants will enter an open label phase (Period 2) during which participants who responded to stimulation will continue on stimulation; whereas participants who received sham stimulation, or were stimulation non-responders, will receive a market-approved RA drug for 12 weeks. At the end of Period 2, participants who respond to their Period 2 therapy but still exhibit signs and symptoms of RA will enter the Treat-to-target period (Period 3); others will proceed to Period 4 (Long-term Follow-up). During the Treat-to-Target period, participants will be treated with dual therapy (stimulation in combination with the market-approved RA drug) for up to 24 weeks. Period 4 provides long term safety follow up for all study participants for a period of 5 years. Participants may receive stimulation in combination with other approved and standard of care therapies, subject to a favorable benefit-risk assessment in the judgement of the treating rheumatologist.

Enrollment

28 estimated patients

Sex

All

Ages

22 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

* RA of at least six months duration, per 2010 ACR/EULAR criteria * Male or female participants, 22-75 years of age * Active RA * Inadequate Response to at least 2 biologic DMARDs and/or JAK-inhibitors (JAKis) including at least one TNF inhibitor * Have an appropriate washout from previously used biological DMARDs or JAKi * Receiving current treatment with standard dose(s) of conventional synthetic DMARD(s) or have documented history of failure due to ineffectiveness or intolerance

Exclusion criteria

* Inability to provide informed consent * Significant psychiatric disease or substance abuse * History of unilateral or bilateral vagotomy * Active or latent tuberculosis * Known infection with human immunodeficiency virus (HIV); current acute or chronic hepatitis B or hepatitis C; previous hepatitis B * Positive SARS COV 2 PCR screening test for COVID-19 infection (at the point of screening for this study) * Currently implanted electrically active medical devices (e.g., cardiac pacemakers, automatic implantable cardioverter-defibrillators) * Previous splenectomy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

Quadruple Blind

28 participants in 7 patient groups

Active Stimulation; Period 1
Experimental group
Description:
Active stimulation for 12 weeks
Treatment:
Drug: Background Treatment
Device: Active Stimulation
Sham Stimulation; Period 1
Sham Comparator group
Description:
Sham stimulation for 12 weeks
Treatment:
Drug: Background Treatment
Device: Sham Stimulation
Open label active stimulation, Period 2
Experimental group
Description:
Open label active stimulation for 12 additional weeks
Treatment:
Drug: Background Treatment
Device: Active Stimulation
Open label RA Drug, Period 2
Other group
Description:
Open label drug treatment with baricitinib for 12 weeks
Treatment:
Drug: Background Treatment
Drug: Baricitinib
RA drug combined with active stimulation, Period 3
Experimental group
Description:
Participants on baricitinib during Period 2 will have active stimulation added for 24 weeks
Treatment:
Drug: Background Treatment
Device: Active Stimulation
Drug: Baricitinib
Active stimulation combined with RA drug, Period 3
Experimental group
Description:
Participants on active stimulation during Period 2 will have baricitinib added for 24 weeks
Treatment:
Drug: Background Treatment
Device: Active Stimulation
Drug: Baricitinib
Long-term Follow-up, Period 4
Other group
Description:
Standard of care treatments with or without stimulation
Treatment:
Drug: Background Treatment
Device: Active Stimulation

Trial contacts and locations

14

Loading...

Central trial contact

Operations Director

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems